RECENSUS / INCEPTUS / ASPIRO Studies
AT132 Gene Therapy for XLMTM – Commonly Asked Questions & Answers
What is INCEPTUS? What is ASPIRO?
Both INCEPTUS and ASPIRO are clinical studies that are being or will be conducted by Audentes Therapeutics. The Audentes gene therapy product for XLMTM is called AT132. INCEPTUS and ASPIRO form part of the clinical development program for AT132. The overall aim of the clinical development program is to evaluate if AT132 is safe and effective in XLMTM, and to get the drug approved quickly in order to benefit patients with XLMTM as rapidly as possible. Audentes will collect the necessary data in the clinical studies and then, if the outcomes from the clinical studies are positive, file an application for potential approval to sell AT132 commercially with regulatory agencies around the world (e.g. FDA in the United States, and EMA in Europe).
Audentes Therapeutics has initiated its first study of X-Linked Myotubular Myopathy (XLMTM), entitled RECENSUS: A Medical Chart Review of Patients with XLMTM. RECENSUS is a Latin word which means to review and investigate. The goal of this study is to collect information from medical charts in order to characterize aspects of the condition and associated medical care for males with XLMTM.
This is a retrospective, non-interventional study, meaning there is a review of past care. It does not require visits to a study site or any medical procedures.
We hope that this study will contribute considerably to the understanding of XLMTM. If you are interested in having your or your child’s medical chart included in the study, please follow the link below for more information about the study and participating sites:
Those patients enrolled in the Begg’s registry do NOT need to do anything else. Their data is already being included in the study. Participation in this study does not influence the selection of patients for the clinical trial.
For any questions, please contact
Barbara H. Wuebbels, RN, MS
Vice President of Patient Advocacy
Audentes Therapeutics Inc.